On this page
Our Team’s Contributions to Myeloma Research
Patient Experience & Quality of Life
Bridging Perspectives: How Canadian Patients and Caregivers View Quality of Life in Multiple Myeloma Compared to Validated Instruments
J. Patenaude, A. Légaré, F. Dupont, Gabriele Colasurdo, Martine Elias, C. Beauchemin, J. Lachaine
Published March 2026 in Current Oncology
Surveyed over 300 Canadian patients and 100 caregivers to compare how they rate their quality of life against what standard clinical questionnaires measure.
Exploring What Matters Most to Patients in Relapsed Refractory Multiple Myeloma Treatment: A Canadian Discrete Choice Experiment with Patients, Caregivers and Physicians
Rebekah Hall, Gin Nie Chua, Bonnie Macfarlane, Richard K. Plante, Kun Shi, Stephanie Soltys, Arleigh McCurdy, Martine Elias, Jessy Ranger
Published July 2025 in BMC Cancer
Surveyed 101 Canadian patients living with relapsed/refractory multiple myeloma, along with 46 caregivers and 49 physicians, on how the disease’s toll on quality of life shapes treatment priorities.
Health Policy, Access & Real-World Evidence
Impact of Systemic Delays for Patient Access to Oncology Drugs on Clinical, Economic, and Quality of Life Outcomes in Canada
Sandeep Sehdev, Joanna Gotfrit, Martine Elias, Barry D. Stein
Published March 2024 in Current Oncology
Reviews the evidence showing how delays in Canada’s drug approval and reimbursement process can cost patients months to years of survival, drain them financially, and diminish their quality of life.
Engaging Patients in the Canadian Real-World Evidence for Value in Cancer Drugs (CanREValue) Initiative
William K. Evans, Pam Takhar, Valerie McDonald, Martine Elias, Louise Binder, Stéphanie Michaud, Mina Tadrous, Caroline Muñoz, Kelvin K. W. Chan
Published August 2022 in Current Oncology
Documents how patient advocates, including Myeloma Canada, helped shape a national framework for using real-world evidence in cancer drug funding decisions, and shares lessons for meaningfully involving patients in that process.
Consensus Guidelines & Clinical Practice Recommendations
Minimal Residual Disease Testing Infrastructure in Multiple Myeloma: Guidance for Clinical Trial and Routine Practice Use in Canada
Hira S. Mian, Alissa Visram, Steven Chun-Min Shih, Suzanne Trudel, Annette E. Hay, Richard LeBlanc, Michael Sebag, Rayan Kaedbey, Julie Stakiw, Irwindeep Sandhu, Chai W. Phua, Philip G. Kuruvilla, Ibraheem Othman, Graeme Quest, David McMullen, Gabriele Colasurdo, Rami Kotb, Christopher P. Venner
Published June 2025 in Clinical Lymphoma, Myeloma & Leukemia
Reviews the current state of minimal residual disease (MRD) testing across Canada and offers practical guidance for using it consistently in both clinical trials and everyday practice.
First Line Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma: Recommendations From a Canadian Consensus Guideline Consortium
Sahar Khan, Debra J. Bergstrom, Julie Côté, Rami Kotb, Richard LeBlanc, Martha L. Louzada, Hira S. Mian, Ibraheem Othman, Gabriele Colasurdo, Alissa Visram
Published March 2025 in Clinical Lymphoma, Myeloma & Leukemia
Canadian expert consensus recommendations for treating newly diagnosed myeloma patients who are eligible for a stem cell transplant.
Recommendations for the Effective Use of T-Cell-Redirecting Therapies: A Canadian Consensus Statement
Guido Lancman, Kevin Song, Darrell White, Tina Crosbie, Ismail Sharif, Marianne Emond, Muhammad Saleem Raza, Martine Elias, Rayan Kaedbey, Michael P. Chu
Published November 2024 in Frontiers in Oncology
Canadian expert consensus on how to select patients, manage referrals, and handle side effects for two of the newest classes of myeloma treatment: CAR-T therapy and bispecific antibodies.
Consensus Guidelines on the Diagnosis of Multiple Myeloma and Related Disorders: Recommendations of the Myeloma Canada Research Network Consensus Guideline Consortium
Debra J. Bergstrom, Rami Kotb, Martha L. Louzada, Heather J. Sutherland, Sofia Tavoularis, Christopher P. Venner, on behalf of the Myeloma Canada Research Network Consensus Guideline Consortium
Published July 2020 in Clinical Lymphoma, Myeloma & Leukemia · Developed with contributions from Myeloma Canada’s Gabriele Colasurdo
National consensus recommendations for diagnosing multiple myeloma and related conditions, aimed at standardizing testing across the country.